Alexion Pharmaceuticals, Inc. · 3 days ago
Next-Generation Conjugates Intern, Rising Seniors and PhD Students
Alexion Pharmaceuticals, Inc. is seeking undergraduate senior and PhD level students for a 12-week internship role. The role involves optimizing cell culture conditions and generating protein to support a new platform technology within the team.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Optimize cell culture conditions to benefit a new platform technology to be used within our team
Generate protein from optimized cell culture conditions to identify lead conditions for subsequent use on the team
Present findings at regular individual meetings with supervisor and at larger group/project team meetings
Qualification
Required
Undergraduate senior and PhD level students majoring in Biomedical Engineering, Biology, Biochemistry, Chemical Engineering, Microbiology or a related discipline. Candidates must have an expected graduation date after August 2026
Required wet lab skills: pipetting, mammalian cell culture, bacterial cell culture, cloning, and molecular biology
Problem-solving skills, documentation, organization, and strong interpersonal skills to work both as a team and independently are crucial for a successful candidate
Ability to report onsite to Gaithersburg, MD 5 days per week. This role will not provide relocation assistance
US Work Authorization is required at time of application
This role will not be providing OPT support
Preferred
Preferred wet lab skills: antibody generation, protein engineering, and protein purification
Benefits
Short-term incentive bonus opportunity
Equity-based long-term incentive program (salaried roles)
Retirement contribution (hourly roles)
Commission payment eligibility (sales roles)
Qualified retirement program [401(k) plan]
Paid vacation and holidays
Paid leaves
Health benefits including medical, prescription drug, dental, and vision coverage
Company
Alexion Pharmaceuticals, Inc.
Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community.
Funding
Current Stage
Public CompanyTotal Funding
$5.8M2020-12-12Acquired
1999-02-12Post Ipo Equity· $5.8M
1996-02-29IPO
Leadership Team
Recent News
bloomberglaw.com
2025-12-20
Company data provided by crunchbase